Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock
Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · May 10, 2019
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called ECMO (Extracorporeal Membrane Oxygenation) for children who are experiencing severe septic shock. Septic shock is a serious condition that can cause the body's organs to stop working properly, and it remains a leading cause of death in children worldwide. The trial aims to find out if ECMO can help improve the chances of survival for these children and determine the best time to start this treatment.
To participate in this study, children must be admitted to the Pediatric Intensive Care Unit (PICU) with septic shock that does not respond to standard treatments. Unfortunately, children with certain severe conditions, like uncontrolled bleeding or significant brain damage, cannot take part. If eligible, participants will receive ECMO, which helps support their heart and lungs while doctors monitor their recovery closely. This trial is currently recruiting participants, and it is an important step in understanding how to better treat children facing this life-threatening condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Children with septic shock and refractory septic shock admitted to the PICU of all the study centers
- Exclusion Criteria:
- • Fatal chromosomal abnormalities (e.g., trisomy 13 or 18)
- • Uncontrolled bleeding
- • Irreversible brain damage
- • After allogeneic bone marrow transplantation
- • Weight less than 2.5kg or severe malnutrition
About Children's Hospital Of Fudan University
The Children's Hospital of Fudan University is a leading pediatric healthcare institution in China, renowned for its commitment to advancing child health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital focuses on conducting high-quality, ethically-driven studies that aim to improve pediatric care and treatment outcomes. With a multidisciplinary team of experienced healthcare professionals and researchers, the hospital leverages its robust infrastructure and expertise to facilitate groundbreaking clinical trials, ensuring the safety and well-being of child participants while contributing valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Guoping Lu, Doctor
Principal Investigator
Children's Hospital of Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials